First episode psychoses: Psychosocial, interpersonal and cognitive bases for a therapeutic approach;Le psicosi all'esordio: Le basi psicosociali, interpersonali e cognitive per un razionale approccio terapeutico

Clinica Terapeutica

Volumn 158, Issue 1, 2007, Pages 85-96

  Di Michele, Vittorio ^a,b,c   Mazza, M ^a   Pollice, R ^a   Bolino, F ^b   Giosue P ^c   Roncone, R ^a   Casacchia, M ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Dipartimento di Salute Mentale   (Italy)

^c NONE

Author keywords

Cognition; Olanzapine; Psychosocial treatments; Quetiapine; Risperidone; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL FEATURE; COGNITION; HUMAN; INTERPERSONAL COMMUNICATION; MENTAL HEALTH SERVICE; PSYCHOSIS; REVIEW; SOCIAL PSYCHOLOGY;

ADOLESCENT; ADULT; ALGORITHMS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS;

EID: 33947253360     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Hafner H, Loffler W, Maurer K et al.: Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand 1999; 100:105-8
2. Edwards J, McGorry PD: Implementing early intervention in psychosis. A guide to establishing early psychosis service. Martin Dunitz, London, 2002
3. Cocchi A, Meneghelli A: L'intervento precoce tra pratica e ricerca. Centro Scientifico Editore, Torino, 2004
4. Lieberman JA, Darlene J, Geisler S: Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry. 1993;50:369-376
5. Robinson D, Woerner MG, Alvir JMJ: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiat 1999; 56:241-7
6. Amminger GP, Resch F, Mutschlechner R, et al.: Premorbid adjustment and remission of positive symptoms in first-episode psychosis. Eur Child Adolesc. Psychiat 1997; 6:212-8
7. Di Michele V, Bolino F: Factors leading to bad social outcome in subjects with psychosis. Epidemiologia e Psichiatria Sociale 2004;13,3:146-51
8. Milton J, Amin S, Singh SP: Aggressive incidents in first episode psychosis. Br J Psychiat 2001; 178:433-40
9. Cohen S, Lavelle J, Rich CL, et al.: Rates and correlates of suicide attempts in first admission psychotic patients. Acta Psychiatr Scand 1994; 90:167-71
10. Steinert T, Wiebe C, Gebhardt RP: Aggressive behavior against self and others among first-admission patients with schizophrenia. Psychiatric Services 1999; 50:85-90
11. McGorry P, Killackey EI: Early intervention in psychosis: a new evidence based paradigm. Epidemiologia e Psichiatria Sociale 2002; 11(4):237-47
12. Jones P, Rodgers B, Murray R, et al.: Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994; 344:1398-402
13. Woods SW: The economic burden of bipolar disease. J. Clin Psychiat 2000; 61(suppl):38-41
14. Finzen A, Hoffmann-Richter U: Stigma and quality of life in mental disorders. In: quality of life in mental disorders. Katschnig H, Freeman H, Sartorius N eds. John Wiley & Sons, 1997
15. Freeman H: Standard of life and environmental factors as components of quality of life in mental disorders. In: Quality of life in mental disorders. Katschnig H, Freeman H, Sartorius N eds. John Wiley & Sons, 1997
16. Garattini L, Barbui C, Clemente R, et al.: Direct costs of schizophrenia and related disorders in Italian community Mental Health Services: a multi-center, prospective 1-year follow up study. Schizophr Bull 2004; 30:295-302
17. de Girolamo G, Picardi A, Micciolo R, et al.: Residential care in Italy: a national survey of non-hospital facility. Br J Psychiat 2002; 181:220-225
18. Tomasi R, de Girolamo G, Santone G, et al.: La prescrizione di psicofarmaci nelle strutture residenziali italiane. Epidemiologia e Psichiatria Sociale 2005; 14:77-90
19. Mezzich JE, Schmolke MM: Quality of life and global clinical diagnosis. In: Quality of life in mental disorders, Katschnig H, Freeman H, Sartorius N eds. John Wiley & Sons 1997
20. Swartz MS, Perkins DO, Stroup TS, et al.: Assessing clinical and functional outcome in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial. Schizophr Bull 2003; 29:33-43
21. Naber D, Vita A: Tools for measuring clinical effectiveness. European Neuropsychopharmacology 2004; 14:8435-44
22. Rush AJ: Toward and understanding of bipolar disorder and its origin. J Clin Psychiat 2003; 64 suppl 6:4-8
23. Schwarzkopf SB, Nasrallh HA, Olson SC: Perinatal complications and genetic loading in schizophrenia: preliminary findings. Psychiatry Res 1989; 27:233-9
24. Penn DL, Corrigan PW, Racenstein JM: Cognitive factors and social adjustment in schizophrenia. In Handbook of social functioning in schizophrenia. Mueser KT & Tarrier N eds. Allyn & Bacon, 1998
25. Spilker B: Quality of life and pharmacoeconomics in clinical trial. Lippincot-Raven Press, New York, 1996
26. Huxley P: Quality of life. In Handbook of social functioning in schizophrenia. Mueser KT & Tarrier N eds. Allyn & Bacon, 1998
27. Arango C, Parellada M, Moreno DM: Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol 2004;14:s471-9
28. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; (suppl)154(4):1-63
29. Kendler KS: Toward a scientific psychiatric nosology. Arch Gen Psychiat 1990; 47:969-73
30. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiat 2003; 60:553-64
31. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004 (suppl)161(2):1-56
32. Patel JK, Pinals DA, Breier A: Schizophrenia and other psychoses. In Psychiatry: Tasman A, Kay J, Lieberman JA eds. John Wiley and Sons, Ltd, Chichester, 2003
33. Tohen M, Chengappa KNR, Suppes T, et al.: Relapse prevention in bipolar I disorder: 18 month comparison of olanzapine plus mood stabiliser v mood stabiliser alone. Br J psychiatry 2004; 184:337-45
34. Calabrese JR, Elhaj O, Gajwani P, et al.: Clinical highlights in bipolar depression: focus on atypical antipsychotics. J clin psychiatry 2005; 66(suppl),5:26-33
35. Berrettini W: Evidence for shared susceptibility in bipolar disorder and schizophrenia. Am J Med Gen Seminal Med Genetics 2003; 123:59-64
36. Murphy FC, Sahakian BJ: Neuropsychology of bipolar disorder. Br J Psychiat 2001178 (suppl):120-7
37. Gershon ES, DeLisi LE, Hamovit J, et al.: A controlled family study of chronic psychoses. Arch Gen Psychiatry 1988; 45:328-36
38. Maier W, Lichtermann D, Minges J, et al.: Continuity and discontinuity of affective disorders and schizophrenia. Arch Gen Psychiatry 1993; 50:871-83
39. Kendler KS, McGuire M, Gruenberg AM, et al.: The Ros-common family study. Arch Gen Psychiat 1993; 50:527-40
40. Green EK, Raybould R, Macgregor S, et al.: Operation of the schizophrenia susceptibility gene, Neureegulin-1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Arch Gen Psychiatry 2005; 62:642-8
41. Kraepelin E: Psychiatrie. Ein Lehrbuch fur Studirende und Aerzte. 5, vollstandig umgearbeitete Auflage. Leipzig: Barth. 1896
42. Ehman T, Hanson L: Social and psychological interventions. In: Best care in early psychosis intervention. Global perspective, eds Ehman T, MacEwan GW, Honer WG. Taylor & Francis, Oxon (UK), 2004; 61-74
43. Jablensky A: Course and outcome of schizophrenia and their prediction. In: New Oxford textbook of psychiatry. Gelder MG, Lopez-Ibor Jr, Andreasen NC eds. Oxford University Press Inc, New York, 2000
44. AIFA: Guida all'uso del farmaco. Masson, Milano, 2005
45. Gerlach J: Improving outcome in schizophrenia: the potential importance of EPS and Neuroleptic dysphoria. Ann Clin Psychiat 2002; 14:47-57
46. Tsuang MT, Stone WS, Faraone SV: Understanding predisposition to schizophrenia: toward intervention and prevention. Can J Psychiat 2002; 47:518-26
47. Lehman AF, Kreyenbhuhl, Buchanan RW, et al.: The schizophrenia patients outcome research team (PORT): update treatment recommendations 2003. Schizophr Bull 2004; 30:193-217
48. Van Putten T, May PR, Marder SR: Response to antipsychotic medication: the doctor's and consumer's view. Am J Psychiat 1984; 14:16-9
49. Ehman T, Hanson L: Pharmacotherapy. In: Best care in early psychosis intervention. Global perspective, eds Ehman T, MacEwan GW, Honer WG. Taylor & Francis, Oxon (UK), 2004; 37-60
50. Saykin AJ, Gur RC, Gur RE: Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiat 1991; 48:618-24
51. Saykin AJ, Shtasel DL, Gur RE, et al.: Neuropsycological deficits in neuroleptic naive patients with first episode schizophrenia. Arch Gen Psychiat 1994; 51:124-31
52. Bleuler E: Praecox oder der Gruppe der Shizophrenien. In: Aschaffenburg G, ed. Hanbuch der Geisteskrankendheiten. Leipzig: Deuticke, 1911
53. Heaton R, Paulsen JS, McAdams LA, et al.: Neuropsychological deficits in schizophrenics: relationship to age, chronicity and dementia. Arch Gen Psychiat 1994; 51:469-76
54. Braff DL, Heaton R, Kuck J: The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Cart Sorting Test results. Arch Gen Psychiat 1991; 891-8
55. Goldberg TE, Gold JM: Neurocognitive deficits in schizophrenia. In: Hirsch SR, Weinberger Dr, eds. Schizophrenia. Oxford, UK: Blackwell Science Ltd, 1995; 146-62
56. Bilder RM, Goldman RS, Robinson D, et al.: Neuropsychology of first-episode schizophrenia initial characterization and clinical correlates. Am J Psychiat 2000; 157:549-59
57. Shallice T: From neuropsychology to mental structure. Cambrige, UK: Cambrige University Press, 1988
58. Servan-Schreiber D, Choen JD, Steingard S: Schizophrenic deficits in processing of context. A test of a theoretic model. Arch Gen Psychiat 1996; 53:1105-12
59. McGhie A, Chapman S, Disorders of attention and perception in earlier schizophrenia. Brit J Med Psychol 1961; 34:103-16
60. Braff DL, Grillon C, Geyer MA: Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiat 1992; 49:206-15
61. Bolino F, Di Michele V, Manna V, et al.: Acoustic and electrically elicited startle reaction: similar patterns of habituation and reflex modifications in humans. Int J Neurosci 1993; 73: 13-21
62. Bolino F, Di Michele V, Di Cicco L, et al.: Sensorimotor gating and habituation evoked by electro-cutaneous stimulation in schizophrenia. Biol Psychiat 1994; 36,10:670-9
63. Clementz BA, Geyer MA, Braff DL: P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol Psychiat 1997; 41:1035-44
64. Gold JM, Harvey PD: Cognitive deficits in schizophrenia. Psychiat Clin North Am 1993; 16:295-12
65. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiat 1996;153: 320-1
66. Rund BR: A review of longitudinal studies of cognitive functions in schizophrenic patients. Schizophr Bull 1998; 24: 425-35
67. Goldstein G, Zubin I: Neuropsychological differences between young and old schizophrenics with and without associated neurological dysfunction. Schizophr Res 1990; 3:117-26
68. Hyde TM, Nawroz S, Goldberg TE: The cognitive decline in schizophrenia? A cross-sectional study. Br J Psychiat 1994; 164:494-500
69. Mockler D, Riordan J, Sharma T: Memory and intellectual deficits do not decline, with age in schizophrenia. Schizophr Res 1997; 26:1-7
70. Hoff AL, Svetina C, Shields G, et al: Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophr Res 2005; 78:27-34
71. Addington J, Saeedi H, Addington D: The course of cognitive functioning in first episode psychosis.: changes over time and impact over outcome Schizophr Res 2005; 78:35-44
72. Stockmeier CA, Dicarlo JJ, Zhang Y, et al.: Characterization of typical and atypical antipsycotic drugs based on in vivo occupancy of serotonin 2 and dopamine 2 receptors. J Pharmacol Exp Ther 1993; 266:1374-84
73. King DJ: Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiat Scand 1994; 380 (Suppl 38):53-8
74. Medalia A, Gold JM, Merriam A: The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 1988; 3:249-71
75. Spohn HE, Strauss ME: Relation of neuroleptic and anticolinergic medication to cognitive function in schizophrenia. J Abnorm Psycol 1989; 98:367-80
76. Cassens G, Inglis AK, Applebaum PS: Neuroleptics: effects of neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990; 16:477-99
77. Albus M, Hubmann W, Ehrenberg C, et al.: Neuropsychological impairment in first-episode and chronic schizophrenic patients. Eur Arch Psych Clin Neurosc. 1996; 246:249-55
78. Kasper S: First episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psych 1999; 60 Suppl 23: 5-9
79. Merlo MC, Kleinlogel H, Koukkou M: Differences in the EEG profiles of early and late responders to antipsycotic treatment in first-episode, drug naive psychotic patients. Schizophr res 1998; 30:221-8
80. Hoff AL, Sakuma M, Wieneke M, et al.: Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiat 1992; 149:898-903
81. Censits DM, Ragland JD, Gur RC, et al.: Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr Res 1997; 24:289-98
82. Riley EM, McGovern D, Mockler D, et al.: Neuropsychological functioning in first-episode psychosis - evidence of specific deficits. Schizophr Res 2000; 43:47-55
83. Sharma T: Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Brit J Psychiat 1999; 174 (Suppl 38):44-51
84. Mortimer AM: Cognitive function in schizophrenia-do Neuroleptics make a difference? Pharmacol, Biochem, Beh 1997; 56:789-95
85. Friedman J, Temporini H, Davis KL: Pharmacological strategies for augmenting cognitive performance in schizophrenia. Biol Psychiat 1999; 45: 1-16
86. Blyler CR, Gold JM: Effetti cognitivi del trattamento con antipsicotici tipici: un'altra prospettiva. In: Cognizione nella schizofrenia. T Sharma e P Harvey eds. Oxford Univ Press, 2002
87. Green MF, Marshall BD, Jr Wirshmg WC, et al.: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiat 1997; 154:799-804
88. Gallholfer B, Lis S, Meyer-Lindenberg A, et al.: Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects. Acta Psychiatr Scand. 1999; Suppl 395:118-28
89. Keefe RS, Silva SG, Perkins DO, et al.: The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 1999; 25: 201-22
90. Harvey PD, Keefe RSE: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158:176-84
91. Bilder RM: Neurocogintive impairment in schizophrenia and how it affects treatment options. Can J Psychiat 1997; 42:255-64
92. Daniel DG, Goldberg TE, Weinberger DR, et al.: Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder a pilot study. Am J Psychiatry 1996; 153:417-9
93. Meyer-Lindenberg A, Gruppe H, Bauer U, et al.: Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine results from a double-blind study. Pharmacopsychiat 1997; 30:35-42
94. Lindenmayer JP, Iskander A, Park M, et al.: Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenics a prospective study. J Clin Psychiatry 1998; 59:521-527
95. Purdon SE, Jones BD, Slip E, et al.: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiat 2000; 57:249-58
96. Harvey PD: Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder, in 2000. Annual Meeting New Research Program and Abstracts Washington, DC, Am Psych Assoc 2000; 149
97. Volavka J, Czobor P, Sheitman B, et al.: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159:255-62
98. Lencz T, Cornblatt B, Bilder RM: Neurodevelopmental models of schizophrenia: pathophysiologic synthesis and directions for intervention research. Psychopharmacol Bull 2001; 35:95-125
99. Christensen BK, Bilder RM: Dual cytoarchitectonic trends: an evolutionary model of frontal lobe functioning and its application to psychopathology. Can J Psychiat 2000; 45:247-6
100. Borison RL: The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatr Scand 1996: 94, 5-11
101. Chengappa KNR, Pollock BG, Parepally H, et al.: Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychoph 2000; 20:311-6
102. Strauss ME, Reynolds KS, Jayaram G, et al.: Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res 1990; 3:127-9
103. Kern RS, Green MF, Marshall BD, et al.: Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biol Psychiat 1998; 44:726-32
104. Borison RL, Arvanitis LA, Miller BG: ICI 204,636, an atypical antipsychotic efficacy and safety in a multicenter, placebo controlled trial in patients with schizophrenia. US SEROQUEL study group. J clinical psychopharmacology 1996; 16:158-169
105. Sharma T: Quetiapine efficacy in functional domains. Eur Neuropsychopharmacol 200; 11:8385-90
106. Velligan DI, Newcomer J, Pultz J, et al.: Does cognitive function improve with quetiapine in comparison to haloperidol Schizophr Res 2001; 53(3)239-48
107. Engl J, Laimer M, Niederwanger A, et al.: Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiat 2005; 10:1089-96
108. Kasper S: Maintenance of long term efficacy and safety of quetiapine in the treatment of schizophrenia. In: Proceeding of the American College of Neuropsychopharmacol Annual Meeting. December 10-14, San Juan, Puerto Rico, 2000
109. Taylor T, ÓToole MS, Walters J, et al.: A prospective follow up of quality of life, well being, side effects and compliance in the treatment of first episode of psychosis. Schizophr Res 2003; 60 suppl:329
110. Kopala LC, Good KP, Milliken H, et al. Treatment of a first episode of psychotic illness with quetiapine:an analysis of 2 year outcome. Schizophr Res 2006; 81:29-39
111. Lewis R: Should cognitive deficit be a diagnostic criterion for schizophrenia? J Psychiat Neurosci 2004; 29(2)102-13
112. Gaebel W, Moller HJ, Buchkremer G, et al.: Pharmacological long-term treatment strategies in first episode schizophrenia. Eur Arc Psy Clin Neurosci 2004; 254:129-140
113. Burns T, Fioritti A, Holloway F, et al.: Case management and assertive community treatment in Europe. Psychiatric Services 2001; 52:631-6
114. McIntyre RS, Brecher M, Paulsson B, et al.: Quetiapine or haloperidol as monotherapy for bipolar mania. A 12 week, double-blind, randomised, parallel group, placebo controlled trial. Eur Neuropsychopharmacol 2005; 15:573-85
115. Hardan AY, Jou RJ, Handen BL: Retrospective study of Quetiapine in children and adolescents with pervasive developmental disorders developmental disorders. J Autism Develop Dis 2005; 35:387-91